Reversible posterior leukoencephalopathy syndrome associated with bevacizumab/doxorubicin regimen

British Journal of Clinical Pharmacology

Volumn 65, Issue 5, 2008, Pages 793-794

  Bürki, Franck ^b   Badie, Kattalin ^a   Bartoli, Philippe ^c   Bernard, Pascale ^d   Montastruc, Jean Louis ^a   Bagheri, Haleh ^a  

^a UNIVERSITÉ PAUL SABATIER   (France)

^b Clinique de l'Union   (France)

^c Clinique de l'Union   (France)

^d Fondation St Jean de Dieu   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; DOXORUBICIN; FUROSEMIDE; MANNITOL; NICARDIPINE; PREDNISONE;

ADULT; BREAST CANCER; CASE REPORT; CEREBROSPINAL FLUID ANALYSIS; CLINICAL EXAMINATION; CLINICAL FEATURE; CONTINUOUS INFUSION; FEMALE; HUMAN; LETTER; LEUKOENCEPHALOPATHY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; POSTERIOR LEUKOENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; SYMPTOMATOLOGY;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DOXORUBICIN; FEMALE; HUMANS; POSTERIOR LEUKOENCEPHALOPATHY SYNDROME;

EID: 42149135942     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2008.03119.x     Document Type: Letter

References (9)

1. Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY, Jain RK. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004 10 : 145 7.
2. Eskens FA, Verweij J. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors: a review. Eur J Cancer 2006 18 : 3127 39.
3. Glusker P, Recht L, Lane B. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 2006 9 : 980 1.
4. Oczan C, Wong SJ, Hari P. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 2006 9 : 980 2.
5. Allen JA, Adlakha A, Bergethon PR. Reversible posterior leucoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metatstatic colon cancer. Arch Neurol 2006 10 : 1475 8.
6. Rixe O, Billemont B, Izzedine H. Hypertension as a predictive factor of sunitinib activity. Ann Oncol 2007 6 : 1117.
7. Martin G. reversible posterior leucoencephalopathy syndrome induced by sunitinib. J Clin Oncol 2007 23 : 3559.
8. Haefner MD, Siciliano RD, Widmer LA, Vogel Wigger BM, Frick S. Reversible posterior leucoencephalopathy syndrome after treatment of diffuse large B-cell lymphoma. Onkologie 2007 3 : 138 40.
9. Edwards MJ, Walker R, Vinnicombe S, Barlow C, MacCallum P, Foran JM. Reversible posterior leucoencephalopathy syndrome following CHOP chemotherapy for diffuse large B-cell lymphoma. Ann Oncol 2001 9 : 1327 9.